Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers create mouse model that develops a human-like lymphoma

17.05.2005


Findings demonstrate that abnormal expression of the BCL6 gene causes lymphoma



Researchers at Columbia University Medical Center have created the first mouse model that develops a lymphoma the same way that humans do. This advancement has the potential to significantly speed the development of new, improved therapies for diffuse large B cell lymphoma (DLBCL), the most common type of human B cell lymphoma. Human B cell lymphomas cause 85 percent of non-Hodgkin’s lymphomas, the sixth leading cause of cancer deaths in the United States.

The findings also confirm that a mutation in BCL6, the gene most frequently altered in this type of lymphoma, is the first step in its development, though other subsequent mutations also occur. In the study, mice with a mutant form of this gene spontaneously developed this lymphoma.


Cancer researchers have long been hindered by the lack of animal models to recreate both the genetics and biology of DLBCL. They had no way to test, with reliable accuracy, how an investigational therapy would work in humans with this disease. Also, this lack of animal models has slowed understanding of the BCL6 gene and its precise role in tumor development.

Published in the May 2005 issue of Cancer Cell, the study was led by Riccardo Dalla-Favera, M.D., one of the world’s leading cancer geneticists and lymphoma researchers. Dr. Dalla-Favera is director of the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center and NewYork-Presbyterian/Columbia. The HICCC is one of only three NIH-designated Comprehensive Cancer Centers in New York State. He is also director of the Institute for Cancer Genetics at Columbia University Medical center.

Dr. Dalla-Favera and his research team genetically engineered mice to produce a mutant BCL6 gene, showing the specific role of this gene in its pathogenesis and displaying most of the critical features of the corresponding human tumor. These findings expand on Dr. Dalla-Favera’s identification of the BCL6 gene in 1994.

"We are very optimistic that this new model for lymphoma will be a catalyst for new therapies for lymphoma; enabling researchers to first test new potential therapies in animals before humans," said Dr. Dalla-Favera, who is also the Percy and Joanne Uris Professor of Pathology and Professor of Genetics & Development at the Columbia University College of Physicians and Surgeons. "We are already using this new model to develop novel therapies targeted to BCL6, so these mice will be valuable in testing these lymphoma-specific compounds."

This mouse model can also be used to identify the additional genetic alterations that are necessary, in addition to BCL6, to develop diffuse large cell lymphoma.

Additional Columbia investigators associated with the Cancer Cell study include: Drs. Giorgio Cattoretti (Columbia’s Institute for Cancer Genetics and Department of Pathology), Laura Pasqualucci (Institute for Cancer Genetics and Department of Pathology), Subhadra V. Nandula (Department of Pathology), Qiong Shen (Institute for Cancer Genetics), Tongwei Mo (Institute for Cancer Genetics), Vundavalli V. Murty (Institute for Cancer Genetics and Department of Pathology), and Gianna Ballon and Wayne Tam (formerly at the Institute for Cancer Genetics, Columbia University, and presently at the Department of Pathology & Laboratory Medicine, Weill Medical College of Cornell University).

Elizabeth Streich | EurekAlert!
Further information:
http://www.cumc.columbia.edu

More articles from Life Sciences:

nachricht Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University

nachricht How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>